请完善您的信息,提交审核升级会员,查看Trichostatin A的详细信息 完成审核- 升级您的专属账户 即刻兑换价值 500 积分的多种礼券

根据当地政策法规的要求,该产品仅对科研客户提供相关信息。
您需要登录/注册您的专属账户,或与客服人员直接联系 确认您的产品用途,通过审核后,即可查看MCE会员专属产品。
Trichostatin A (TSA) 是有效的,特异的组蛋白去乙酰化酶类型 I 和 II (HDAC class I/II) 抑制剂,对 HDAC 的 IC50 值为 1.8 nM。

1.客户无需承担相应的运输费用。

2.同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

可免费申领三个不同产品的试用装。

3.试用装只面向终端客户。


SDL screens for TDP1 and validation pipeline. Acetylation levels after treatment with TSA in RMS (RH30) cells.
PPARγ lysine 240 and 265 are essential for PPARγ acetylation-associated Klotho derepression. Cellular PPARγ acetylation assay. Human embryonic kidney 293 (HEK293) or human proximal tubular epithelial cells (HK2) cells are treated with trichostatin A (TSA) (100 ng/mL) for 4 hours then subjected to immunoprecipitation with anti-PPARγ antibody. Acetylated PPARγ is detected with a pan anti-acetyl-lysine (ac-K) antibody by Western blotting (WB). The cell lysates are also assayed for total PPARg, Klot
Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC[1].

Trichostatin A is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC. Trichostatin A (TSA) inhibits proliferation of eight breast carcinoma cell lines with mean±SD IC50 of 124.4±120.4 nM (range, 26.4-308.1 nM). HDAC inhibitory activity of Trichostatin A is similar in all cell lines with mean IC50 of 2.4±0.5 nM (range, 1.5-2.9 nM)[1]. Trichostatin A (330 nM) increases Gαs protein expression in human myometrial cells, but does not increase Gαs mRNA levels[2]. Trichostatin A (20-75 nM) induces minimal cytotoxicity to adipose-derived stem cells (ADSCs), and enhances the osteogenic differentiation capacity of ADSCs[3]. In addition, Trichostatin A (0, 10, 100, 500 nM) dose-dependently decreases HDAC class I/II activity[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Trichostatin A (500 μg/kg, s.c.) pronounces antitumor activity without causing any measurable toxicity in doses of up to 5 mg/kg by s.c. injection, in randomized controlled efficacy studies using the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。


请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶


请依序添加每种溶剂:10% DMSO40% PEG3005% Tween-8045% saline

Solubility: 2.5 mg/mL (8.27 mM); Suspended solution; Need ultrasonic


此方案可获得 2.5 mg/mL (8.27 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

请依序添加每种溶剂:10% DMSO90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution


此方案可获得 ≥ 2.5 mg/mL (8.27 mM,饱和度未知) 的澄清溶液。

以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明

请依序添加每种溶剂:5% DMSO40% PEG3005% Tween-8050% saline

Solubility: 2.5 mg/mL (8.27 mM); Suspended solution; Need ultrasonic


请依序添加每种溶剂:5% DMSO95% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution


Cells are cultured in a 96-well plate at 1×103 cells per well with 100 μL complete DMEM in the presence or absence of a HDAC inhibitor Trichostatin A for 72 h. Cytotoxicity is measured by performing WST-8 assay using a CCK-8 cell proliferation kit. The 450 nm absorbance is measured with a microplate reader. All experiments are carried out in triplicate and 3 independent experiments are performed[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Rats[1]
Twelve rats are randomized to receive 500 μg/kg Trichostatin A in 50 μL DMSO, or 50 μL DMSO as vehicle control, by s.c. injection twice weekly for 4 weeks. In subsequent studies, 30 rats are randomized to receive Trichostatin A 500 μg/kg in 50 μL DMSO, or 50 μL DMSO as vehicle control, by s.c. injection daily for 4 weeks. Weekly tumor measurements, estimated tumor volumes, and body mass are recorded for each animal. Animals are sacrificed at the end of the 4-week study period; palpable tumors are resected and immediately snap-frozen in liquid nitrogen. Animals with tumors [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2


Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.


MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。 站点地图 隐私声明